

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/648,864	08/25/2000	Howard M Johnson	UF-243X	6790
23557	7590 10/09/2003		EXAM	INER
	CHIK LLOYD & SALIW	ANDRES, JANET L		
A PROFESSIONAL ASSOCIATION 2421 N.W. 41ST STREET SUITE A-1 GAINESVILLE, FL 326066669			ART UNIT	PAPER NUMBER
			1646	
			DATE MAILED: 10/09/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summary	09/648,864	JOHNSON ET AL.				
Office Action Cummary	Examin r	Art Unit				
The MAILING DATE of this communication app	Janet L. Andres ears on the cover sheet w					
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status						
1) Responsive to communication(s) filed on <u>08 September 2003</u> .						
	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims						
4)⊠ Claim(s) <u>25 and 30-39</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>25 and 30-39</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9)☐ The specification is objected to by the Examiner.						
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) The oath or declaration is objected to by the Examiner.						
Priority under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) All b) Some * c) None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 						
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).						
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152) .				

Application/Control Number: 09/648,864

Art Unit: 1646

RESPONSE TO AMENDMENT

1. Applicant's amendment filed 8 September 2003 is acknowledged. Upon further consideration, the finality of the previous office action is withdrawn. Claims 25 and 30-39 are pending and under examination in this application. The text of those sections of Title 35, U.S. Code, not included in this action can be found in a prior office action.

Claim Rejections Withdrawn

2. Applicant's declaration under 37 CFR 1.132 has been fully considered and is sufficient to overcome the rejection of claims 25 and 30-39 under 35 U.S.C. 103. It is agreed that, based on the teachings of the prior art, one of ordinary skill would not have expected interferon τ to have precisely the same effects as interferon α and thus would not have known whether interferon τ would affect IgE levels.

New Grounds of Rejection

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 4. Claims 25 and 33-39 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by U.S. patent 5,906,816 (Soos et al., May 25, 1999)

Application/Control Number: 09/648,864 Page 3

Art Unit: 1646

The '816 patent teaches mammalian interferon τ in, for example, column 6, lines 36-67. The '816 patent teaches that it is useful for the treatment of autoimmune disease in, for example, column 5, lines 50-63, column 9, lines 64-67, column 10, lines 1-63, and claims 1-11. Such treatment would inherently result in the suppression of IgE production, regardless of whether this suppression or the mechanism by which it was achieved was recognized. Thus the '816 patent anticipates the limitations of claim 25. Any person suffering from an autoimmune disease who also suffered from allergy would be in need of such suppression and the limitations of claims 33-39 are thus also anticipated. Use for treatment of allergy is also specifically taught in column 5, lines 40-63. In vitro administration, as claimed in claim 38, is taught in column 9, table 2.

5. Claims 25, 30-37, and 39 are rejected under 35 U.S.C. 102(a) and 102(e) as being anticipated by U.S. patent 5,939,286 (Johnson et al., August 17, 1999).

The '286 patent teaches interferon τ chimeras with human interferon α in column 5, lines 39-45 and treatment of immune system disorders including allergy in column 32, lines 30-53. Methods of treatment are also claimed in claims 7-9. As stated above, such treatment would inherently result in the instantly claimed effects, regardless of whether the effects were recognized. Thus the '286 patent anticipates claims 25, 30, 31, 33-37, and 39. While interferon α D, claimed in instant claim 32, is not specifically described as a fusion partner in the '286 patent, the patent states that the numerous forms of interferon α which are included, and points to references describing them (column 25, lines 41-59). Thus the fusion with interferon α D is also anticipated.

NO CLAIM IS ALLOWED.

Application/Control Number: 09/648,864 Page 4

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet Andres, Ph.D., whose telephone number is (703) 305-0557. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564. The fax phone number for this group is (703) 872-9306 or (703) 872-9307 for after final communications.

Communications via internet mail regarding this application, other than those under U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov].

All Internet email communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Janet Andres, Ph.D. October 7, 2003

LORRAINE SPECTOR PRIMARY EXAMINER